This has been explained many times, but the reason we have moved...

This has been explained many times, but the reason we have moved to advancing RC220 over RC110 is RC220 solves the problem (drug precipitation in the blood) that prevented bisantrene being commercially viable outside of AML. Solving this problem opens up a market potential for bisantrene more than 100x the potential of RC110 in AML. As RC220 can be used everywhere RC110 can be used (i.e. AML) then it makes RC110 now redundant.

As for why now, RC220 had to be invented first. Lederle (the original developers of bisantrene) tried for years to create something like RC220 without success. Thanks to the hard work and skill of the scientists at RAC we were able to solve this very difficult problem, but it took quite some time - the RC220 project started back in early 2020, but didn't get to proof-of-concept (POC) until late 2022 and is now only drawing to a close in regards GMP manufacturing and GLP toxicity testing. It typically takes around 5 years to get from POC to a clinical product ready for Phase 1, but we have been able to do this somewhat faster thanks to the skill and hard work of the scientists at RAC.